The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

The full lineup of late-breaking clinical science to be presented at THT 2025: Technology and Heart Failure Therapeutics is now available online. Organized by the Cardiovascular Research Foundation® ...